Diabetes Drug Shows Promise for Addiction Treatment

A medication millions take for diabetes and weight loss might hold surprising hope for the 50 million Americans living with addiction.

New research published in The BMJ analyzed health records from over 600,000 veterans and found something remarkable. People taking GLP-1 drugs like semaglutide had fewer emergency room visits, hospitalizations, and deaths related to substance use disorders spanning alcohol, opioids, cannabis, cocaine, and nicotine.

The findings build on years of anecdotal reports from patients who noticed something unexpected while taking their diabetes medication. Their urges to drink or use drugs simply faded away.

"The fact that the results were consistent across substance types really elevates the notion that these medications are acting on the root causes of all of these addictions," said Dr. Ziyad Al-Aly, the clinical epidemiologist who led the study at Washington University in St. Louis.

Researchers used a technique called emulated target trials, analyzing existing data with the same rigor as traditional clinical trials. They compared outcomes for people taking GLP-1 drugs versus another diabetes medication called SGLT2 inhibitors. The GLP-1 group showed better results across every substance type tested.

The theory centers on how these drugs affect the brain's reward system. Just as people report a quieting of "food noise" when taking GLP-1s for weight loss, something similar may happen with substance cravings.

"I think something similar is happening with that preoccupation with needing a substance," Al-Aly explained. "It quiets."

The Ripple Effect

This breakthrough matters because current addiction treatments remain limited. The FDA has approved medications for alcohol, opioid, and nicotine addiction, but nothing exists for cannabis, cocaine, or sedatives. Even existing treatments face high relapse rates.

A single medication that could address multiple types of addiction would transform care for millions. Few people with substance use disorders currently receive any treatment, according to the National Institute on Drug Abuse.

Christian Hendershot, director of clinical research at the USC Institute for Addiction Science, noted that clinical trials are already underway to test GLP-1s for addiction with more rigor. Results should arrive within the next few years.

Researchers caution that no single medication works for everyone with substance use disorders. Addiction involves complex factors, and different treatments help different people. But for those who respond to GLP-1s, the impact could be life-changing.

The study also suggested these drugs might prevent substance use disorders from developing in the first place, though experts called this finding less conclusive than the treatment results.

Decades of searching for better addiction treatments may have found an unexpected ally in a diabetes drug that's already helping millions live healthier lives.